BrainStorm Cell Therapeutics Inc. (NASDAQ:BCLI) saw unusually-high trading volume on Thursday . Approximately 139,842 shares traded hands during trading, an increase of 33% from the previous session’s volume of 105,350 shares.The stock last traded at $2.53 and had previously closed at $2.47.

Separately, Maxim Group set a $5.00 price objective on shares of BrainStorm Cell Therapeutics and gave the company a “buy” rating in a research note on Thursday, August 11th.

The stock’s market capitalization is $47.66 million. The company’s 50-day moving average is $2.54 and its 200 day moving average is $2.43.

BrainStorm Cell Therapeutics (NASDAQ:BCLI) last announced its quarterly earnings data on Thursday, August 11th. The biotechnology company reported ($0.05) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.18) by $0.13. Equities analysts forecast that BrainStorm Cell Therapeutics Inc. will post ($0.34) EPS for the current year.

Brainstorm Cell Therapeutics Inc is a biotechnology company. The Company is engaged in developing adult stem cell therapies for debilitating neurodegenerative disorders, such as Amyotrophic Lateral Sclerosis (ALS, also known as Lou Gehrig’s disease), Multiple Sclerosis (MS) and Parkinson’s disease (PD), among others.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.